Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Clinical trial NCT03080805 · UNKNOWN

Trial details

NCT number: NCT03080805
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

HER2 Positive Metastatic Breast Cancer

Start date: 2017-05-03
Primary completion: 2019-03-31
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.